Fig 2. Growth inhibition.
The lowest effective concentration of a methionyl-tRNA synthetase inhibitor required to inhibit the growth of B. melitensis strain 16M (MIC) was assessed from values observed over concentrations ranging from 0.716–71.6 μg/mL for compound 1433, 0.696–69.6 μg/mL for 1415 while 1312 was determined at inhibitor concentration 0.865–37.6 μg/mL. Average growth (OD450 nm) at 28 hours (late log phase), 37°C, in Brucella minimal medium was measured. Inhibitor 1415 MIC = 53.93μg/mL; Inhibitor 1433 MIC = 38.67 μg/mL; Inhibitor 1312, MIC = 28.96 μg/mL. Control = gentamicin, no growth, 0.7–50 μg/mL; DMSO control has no inhibition of bacterial growth. Data table shows MICs from B. melitensis growth inhibition and IC50s of inhibitors (Kinase-Glo®, aminoacylation assays). The characteristics of each inhibitor experimentally measured against human mitochondria MetRS, EcMetRS, human liver hepatocellular (Hep G2) and lymphocytic (CRL-8155) cell lines are also shown.